The microbiota-derived HDAC inhibitor butyrate can be absorbed into the circulation from the gastrointestinal tract and exhibit physiological effects in many tissues, suggesting that butyrate and other gut microbial metabolites could be critical contributors to cardiovascular and lung diseases [8,19,24,50]. This evidence concerns the gene HDAC9 and lung disorder.